Protara Therapeutics (TARA) Operating Expenses (2013 - 2026)

Protara Therapeutics (TARA) has reported Operating Expenses for 14 consecutive years, with $19.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Operating Expenses rose 38.98% year-over-year to $19.6 million; the TTM figure through Mar 2026 stood at $70.1 million (up 36.22% YoY), while the FY2025 annual figure was $64.5 million, up 31.32% from the prior year.
• Operating Expenses improved to $19.6 million in Q1 2026 per TARA's latest filing, from $19.1 million in the prior quarter.
• Across five years, Operating Expenses topped out at $39.5 million in Q4 2022 and bottomed at $8.0 million in Q3 2022.
• Historically, Operating Expenses has averaged $14.4 million across 5 years, with a median of $12.1 million in 2023.
• Annual changes were most pronounced in 2022 — Operating Expenses jumped 284.07% — and 2023, when it sank 72.05%.
• Protara Therapeutics' Operating Expenses stood at $39.5 million in 2022, then tumbled by 72.05% to $11.0 million in 2023, then climbed by 29.63% to $14.3 million in 2024, then soared by 33.31% to $19.1 million in 2025, then increased by 2.88% to $19.6 million in 2026.
• Business Quant data shows TARA's Operating Expenses at $19.6 million in Q1 2026, $19.1 million in Q4 2025, and $14.8 million in Q3 2025.